Can a hormone drug help restore skin color in vitiligo?

NCT ID NCT07437560

Recruiting now Disease control Sponsor: Hudson Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests whether adding Melanotan II (a synthetic hormone-like drug) to standard narrowband UV-B light therapy helps restore skin color in adults with stable nonsegmental vitiligo. About 60 participants will receive either the drug or a placebo, plus light therapy, for several months. Researchers will measure changes in skin pigmentation and track how quickly repigmentation occurs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melanotan II (a synthetic hormone-like drug) plus narrowband UV-B phototherapy
What this could lead to: If it works, this could offer a new treatment option to restore skin color in people with stable vitiligo.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or not improve repigmentation more than light therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONSEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized vitiligo skin pigmentation disorder vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONSEGMENTAL VITILIGO NONSEGMENTAL VITILIGO (STABLE)

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.